Navigation Links
Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
Date:8/27/2009

SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company has begun a clinical trial intended to secure U.S. regulatory approval of its PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.

"Based on the results of our extensive clinical research studies and our European commercial experience, we believe that our PROGENSA PCA3 assay can help predict the risk of a positive follow-up biopsy, thereby improving patient care," said Eric Lai, PhD, Gen-Probe's senior vice president of research and development. "In addition, this is an important step forward in our efforts to maximize the economic value of our oncology strategy."

The clinical study of the PROGENSA PCA3 assay is expected to conclude in less than a year, after which Gen-Probe intends to submit a Premarket Approval Application (PMA) to the U.S. Food and Drug Administration. The Company anticipates the trial will enroll approximately 500 men, all of whom have had a negative prostate biopsy, at 10 or more clinical trial sites.

Data from more than 20 peer-reviewed publications suggest that the PROGENSA PCA3 assay, when used in conjunction with other patient information, may help address some of the well-known challenges urologists face when identifying prostate cancer, such as minimizing unnecessary biopsies.

According to the American Cancer Society (ACS), prostate cancer is the second most common type of cancer found in American men (behind skin cancer), and the second-leading cause of cancer death in men (after lung cancer). One in six American men will get prostate cancer during his lifetime, and one in 35 will die from it. The ACS estimates that more than 19
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
2. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
3. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
4. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
5. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
6. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
7. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
8. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
9. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
10. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
11. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... N.C. , Feb. 27, 2015 Pharmaceutical ... of managing multiple products for the same indication. This ... those that want to prevent one of their brands ... According to recent research by benchmarking firm, ... products as independent brands rather than together as part ...
(Date:2/27/2015)... 27, 2015  Acsis Inc., the market leader for ... today that John DiPalo , Acsis, Chief Strategy ... Demand Chain Executive 2015 Provider Pro to Know. ... initiatives to help prepare their companies, and customers, supply ... This year,s list of Provider Pros to Know is ...
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 /PRNewswire/ - ESSA ... Bloom Burton & Co. Ltd. ("Bloom Burton") today announced ... "Lock-Up") 2,353,130 common shares of the Company ("Common Shares") ... the Lock-Up. Of the Common Shares released from the ... release from the Lock-Up while the remainder will be ...
Breaking Medicine Technology:New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4
... June 21 TMS Health, a leading Healthcare Communications Company ... PA. , , ... TMS Health has enjoyed strong growth as a specialized healthcare ... and marketing reach of its clients. The company provides solutions for ...
... Ethicon Endo-Surgery, Inc. (EES), today introduced a new ... HARMONIC ACE® 45 cm Curved Shears. HARMONIC ACE® 45 ... minimally invasive procedures involving obese patients, is 25 percent ... device. The additional length of the HARMONIC ACE® 45 ...
Cached Medicine Technology:TMS Health Announces New State-of-the Art Facility in Moosic, PA 2Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 2Ethicon Endo-Surgery Introduces HARMONIC ACE® 45 cm Curved Shears at ASMBS 3
(Date:2/28/2015)... A case management conference ( http://www.testosteronelawsuithub.com/ ... filed by law firms including Bernstein Liebhard LLP has ... Firm notes. , According to a Calendar posted ... litigation will meet on March 13, 2015 at 1:30 ... designed to raise levels of the male hormone. The ...
(Date:2/28/2015)... Toronto, ON (PRWEB) February 28, 2015 ... pleased to announce that they have officially relaunched their ... only more user-friendly, but it contains a new section ... have access to read the full biographies of each ... updated portion of the website was designed to provide ...
(Date:2/28/2015)... “ Powermod ” was featured on NewsWatch as part of ... latest and coolest technology products and services available to consumers. ... expert, conducted the review and shared with viewers how they ... with a low battery and no way to charge a ... a daily basis. Even when a person does have a ...
(Date:2/28/2015)... My Shiney Hiney® LLC., the renowned brand in personal ... Nevada for the annual ASD Market Week tradeshow. , ... tradeshows and My Shiney Hiney will be one of the ... can be found at booth number C1663. , My Shiney ... hygiene brush and cleansing system exclusively created to clean and ...
(Date:2/27/2015)... OnChip Devices , a world leader ... bondable, silicon ESD (Electrostatic Discharge) protection diodes targeted for ... ESD88NP and ESD88PN are designed to ... IC products. These Zeners exhibit no device degradation ... meet the requirements of IEC61000 and safely dissipate ESD ...
Breaking Medicine News(10 mins):Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:Friedman Dental Group Announces Their Updated Website 2Health News:Solutions to Keep Phones Charged were Featured on NewsWatch Television on January 29, 2015 2Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3
... neural stem cells and their potential for someday treating diseases ... identified “cancer stem cells,” a small population of cells that ... brain tumor. Theoretically, if these mother cells can be destroyed, ... the other hand, if these cells are not removed or ...
... China's growing strengths in medical research, British Prime Minister ... medical excellence cluster' comprising// universities and drugs companies. ... England to protect Britain's science base and boost its ... of measures initiated by government functionaries while citing the ...
... of becoming infected with lymphocytic choriomeningitis virus (LCMV), an ... that can cause severe brain damage in a fetus. ... in the winter months, when rodents seek shelter in ... pediatrics at the University of Iowa Roy J. and ...
... was strongly believed since its launch that the doctor ... out any polyps, which is the main source// of ... in The New England Journal of Medicine says that ... out some polyps resulting in the development of life-threatening ...
... the Rajiv Gandhi Center’s Biotechnology and Regional Cancer Centre ... treating radiation related mucositis. // ,The mouthwash is ... effective in the treatment of mucositis, which is one ... radiation. Few of the symptoms are mouth sores and ...
... said Friday it would not withdraw a notification making ... and crossbones picture //as a warning but said its ... Sabha MPs from various parties protested the move saying ... workers. ,However, Health Minister Anbumani Ramadoss said ...
Cached Medicine News:Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 2Health News:Genes That Allow Brain Cancer-Causing Stem Cells to Resist Treatment Identified 3Health News:Britain Plans Medical Hub to Meet India, China Challenge 2Health News:Pregnant Women Can Minimize Risk Of Rodent-Based Virus 2Health News:A Study Questions the Effectiveness of High Speed Colonoscopies 2
... The BreatheX is a wearable CPAP ... treatment of sleep apnea. The lightweight BreatheX ... of therapy with its built-in, rechargeable battery, ... users will no longer need to be ...
Paraffin Block Storage System...
Shandon Paraffin Block Cabinet...
The Tissue Cassette Storage Cabinet is made of strong, laminated fiberboard....
Medicine Products: